AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15782623 — intervention group
Group type: COMPARATOR
Intervention: Peg-interferon alfa-2b 1.5mcg/Kg s.c./once-weekly (group C)
Number of subjects: 78
Study 11556733 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 3 cmH2O
Number of subjects: 19
Study 11556733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 3 cmH2O with PEEP of 3 cmH2O
Number of subjects: 19
Study 9812658 — intervention group
Group type: EXPERIMENTAL
Intervention: Biminkang mixture
Number of subjects: 216
Study 9812658 — intervention group
Group type: COMPARATOR
Intervention: Biyankang (control)
Number of subjects: 216
Study 7954244 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (48.0 Gy or 54.4 Gy)
Number of subjects: 177
Study 7954244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose (64.8 Gy or 72.0 Gy)
Number of subjects: 177
Study 7954244 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (76.8 Gy or 81.4 Gy)
Number of subjects: 177
Study 7954244 — intervention group
Group type: COMPARATOR
Intervention: Low vs. Intermediate dose
Number of subjects: 177
Study 7954244 — intervention group
Group type: COMPARATOR
Intervention: Intermediate vs. High dose
Number of subjects: 177
Study 7954244 — intervention group
Group type: COMPARATOR
Intervention: Low vs. High dose
Number of subjects: 177
Study 3117477 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine bicycle exercise at 12 W with varying pedalling rates (30-50 cycles/min)
Number of subjects: 15
Study 3117477 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine bicycle exercise at 37 W with varying pedalling rates (30-50 cycles/min)
Number of subjects: 15
Study 3117477 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine exercise at 12 W
Number of subjects: 15
Study 3117477 — intervention group
Group type: COMPARATOR
Intervention: Comparison of males and females during exercise
Number of subjects: 15
Study 2790695 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine treatment plus five-drug chemotherapy (CMFVPT)
Number of subjects: 94
Study 2790695 — intervention group
Group type: COMPARATOR
Intervention: Endocrine treatment (tamoxifen [T], 40 mg daily for 3 years)
Number of subjects: 94
Study 30796973 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels
Number of subjects: 98
Study 30796973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia episodes
Number of subjects: 98
Study 30796973 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-positive patients
Number of subjects: 98
Study 31652010 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative binomial distribution sample size calculation method
Number of subjects: 0
Study 31652010 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of slopes
Number of subjects: 0
Study 31652010 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of time-averaged responses
Number of subjects: 0
Study 27557955 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-site infiltration analgesia (MIA)
Number of subjects: 77
Study 27557955 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 77
Study 27557955 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 77
Study 26742306 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera syrup (10 mL/d, standardized to 5.0 mg polysaccharide per mL)
Number of subjects: 79
Study 26742306 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole capsule (20 g/d)
Number of subjects: 79
Study 26742306 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine tablet (150 mg in a fasted state in the morning and 150 mg 30 min before sleep at night)
Number of subjects: 79
Study 23825422 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down expectation
Number of subjects: 0
Study 23825422 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional precision
Number of subjects: 0
Study 23825422 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit top-down expectation
Number of subjects: 0
Study 23825422 — intervention group
Group type: EXPERIMENTAL
Intervention: Drift of the CNV
Number of subjects: 0
Study 23825422 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus predictability
Number of subjects: 0
Study 23825422 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 21707983 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nicardipine
Number of subjects: 226
Study 21707983 — intervention group
Group type: COMPARATOR
Intervention: IV labetalol
Number of subjects: 226
Study 19743936 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% chitin‐glucan formulation
Number of subjects: 30
Study 19743936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19743936 — intervention group
Group type: COMPARATOR
Intervention: Glycerol formulations
Number of subjects: 30
Study 16500394 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet interface for assessment of endoscopic still images
Number of subjects: 4
Study 16500394 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet interface for assessment of video clips from DVDs
Number of subjects: 4
Study 16500394 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality video assessment
Number of subjects: 4
Study 16061111 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-sulbactam (Ax/S) at a dosage of 80 mg/(kg day), b.i.d. for 10 days
Number of subjects: 289
Study 16061111 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid (Ax/C) at a dosage of 80 mg/(kg day), b.i.d. for 10 days
Number of subjects: 289
Study 11341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised, controlled trials with inadequate sample sizes
Number of subjects: 33
Study 11341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Average sample size used in studies
Number of subjects: 33
Study 9762567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin produced and formulated in the People's Republic of China
Number of subjects: 133
Study 9762567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin produced in Vietnam but formulated by the Government Pharmaceutical Organization of Thailand
Number of subjects: 133
Study 9762567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin produced and formulated by the Government Pharmaceutical Organization of Thailand
Number of subjects: 133
Study 9762567 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 133
Study 7871074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol alone
Number of subjects: 14
Study 7871074 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana alone
Number of subjects: 14
Study 7871074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and marijuana in combination
Number of subjects: 14
Study 7871074 — intervention group
Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 14
Study 3060430 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 3060430 — intervention group
Group type: COMPARATOR
Intervention: Propranolol with Indomethacin
Number of subjects: 10
Study 3060430 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 10
Study 31425359 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw thrust test
Number of subjects: 30
Study 28493943 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Lung Approach (OLA) with individualized PEEP (8±2 cmH2O)
Number of subjects: 36
Study 28493943 — intervention group
Group type: COMPARATOR
Intervention: Standard PEEP of 5 cmH2O (RM-5 group)
Number of subjects: 36
Study 25947566 — intervention group
Group type: EXPERIMENTAL
Intervention: Elisidepsin (PM02734) administered as a 30-min intravenous infusion every 3 weeks (q3wk) at doses ranging from 0.1 to 1.6 mg/m(2)
Number of subjects: 53
Study 25947566 — intervention group
Group type: EXPERIMENTAL
Intervention: Elisidepsin (PM02734) administered as a 3-hour intravenous infusion every 3 weeks (q3wk) at doses ranging from 2.0 to 11.0 mg flat dose (FD)
Number of subjects: 53
Study 23595408 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper quartile average of esophageal temperature
Number of subjects: 106
Study 23595408 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper quartile average of skin temperature
Number of subjects: 106
Study 21663994 — intervention group
Group type: COMPARATOR
Intervention: 4 weeks of guideline-based pulmonary rehabilitation (PR)
Number of subjects: 19
Study 21663994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten preoperative PR sessions using a customized protocol
Number of subjects: 19
Study 21663994 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study 19919789 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (AP) administered 2 hours before incision and continued for 24 hours (Experimental Group, EG)
Number of subjects: 171
Study 19919789 — intervention group
Group type: COMPARATOR
Intervention: Traditional antibiotic scheme administered just before, during, or after incision and continued for 5 days (Control Group, CG)
Number of subjects: 171
Study 17043614 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cold blood cardioplegia enriched with potassium‐magnesium aspartate
Number of subjects: 40
Study 17043614 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine institutional cold blood cardioplegia)
Number of subjects: 40
Study 12759292 — intervention group
Group type: EXPERIMENTAL
Intervention: Total direct costs for RA patients
Number of subjects: 338
Study 12759292 — intervention group
Group type: EXPERIMENTAL
Intervention: RA related direct costs
Number of subjects: 338
Study 12759292 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient costs
Number of subjects: 338
Study 12759292 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient costs
Number of subjects: 338
Study 12759292 — intervention group
Group type: EXPERIMENTAL
Intervention: Other disease related costs
Number of subjects: 338
Study 12759292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost drivers for outpatients
Number of subjects: 338
Study 12759292 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs incurred by prematurely retired patients
Number of subjects: 338
Study 12759292 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs incurred by gainfully employed patients
Number of subjects: 338
Study 11530117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin (80 U/500 mL) infused at 2667 mU/min
Number of subjects: 321
Study 11530117 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin (10 U/500 mL) infused at 333 mU/min
Number of subjects: 321
Study 11530117 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin (10 U/500 mL)
Number of subjects: 321
Study 9249230 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet plus sodium tablets (80 mmols/day)
Number of subjects: 17
Study 9249230 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet plus placebo tablets
Number of subjects: 17
Study 9249230 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 17
Study 7506167 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide 100mg twice daily for 8 days
Number of subjects: 60
Study 7506167 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 3545674 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin concentration of 5 U/ml
Number of subjects: 470
Study 3545674 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin flow rate of 2 ml/h
Number of subjects: 470
Study 3545674 — intervention group
Group type: COMPARATOR
Intervention: Heparin flow rate of 1 ml/h
Number of subjects: 470
Study 31886828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin and 2% chlorhexidine‐impregnated cloths (active treatment, n = 117)
Number of subjects: 236
Study 31886828 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum intranasal ointment and nonmedicated soap cloths (placebo, n = 119)
Number of subjects: 236
Study 31886828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin and 2% chlorhexidine‐impregnated cloths (active treatment)
Number of subjects: 236
Study 31886828 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum intranasal ointment and nonmedicated soap cloths (placebo)
Number of subjects: 236
Study 29505744 — intervention group
Group type: EXPERIMENTAL
Intervention: VR combined with functional electrical stimulation (FES)
Number of subjects: 48
Study 29505744 — intervention group
Group type: COMPARATOR
Intervention: Cyclic FES
Number of subjects: 48
Study 27146819 — intervention group
Group type: EXPERIMENTAL
Intervention: Medially directed patellar realignment brace with supervised physiotherapy
Number of subjects: 156
Study 27146819 — intervention group
Group type: COMPARATOR
Intervention: Supervised physiotherapy alone
Number of subjects: 156
Study 24670340 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 60
Study 24670340 — intervention group
Group type: COMPARATOR
Intervention: Phenol application
Number of subjects: 60
Study 22211088 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 494
Study 22211088 — intervention group
Group type: COMPARATOR
Intervention: Training set
Number of subjects: 494
Study 22211088 — intervention group
Group type: COMPARATOR
Intervention: Validation set
Number of subjects: 494
Study 20453022 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 consecutive nights of 4 hours time in bed (TIB)
Number of subjects: 136
Study 20453022 — intervention group
Group type: EXPERIMENTAL
Intervention: Further sleep restriction (n = 27)
Number of subjects: 136
Study 20453022 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sleep opportunity (n = 37)
Number of subjects: 136
Study 20453022 — intervention group
Group type: COMPARATOR
Intervention: Control condition (10 hr TIB on all study nights, n = 9)
Number of subjects: 136
Study 18035196 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt cessation of guanfacine ER (1 mg to 4 mg over 16 days, then placebo from days 17 to 32)
Number of subjects: 45
Study 18035196 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper-down of guanfacine ER (1 mg to 4 mg over 16 days, then taper down from 3 mg to placebo over 16 days)
Number of subjects: 45
Study 18035196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered daily from days 1-32)
Number of subjects: 45
Study 15656812 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times weekly for 8 weeks, daily for 8 weeks, then daily with occlusion for 8 weeks
Number of subjects: 15
Study 15656812 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 15
Study 12521705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 200
Study 12521705 — intervention group
Group type: COMPARATOR
Intervention: Surgical evacuation under general anaesthesia
Number of subjects: 200
Study 10460041 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 3851
Study 10460041 — intervention group
Group type: COMPARATOR
Intervention: Iodine tincture
Number of subjects: 3851
Study 10460041 — intervention group
Group type: EXPERIMENTAL
Intervention: Contaminated blood cultures
Number of subjects: 3851
Study 7629322 — intervention group
Group type: EXPERIMENTAL
Intervention: NMAB
Number of subjects: 0
Study 7629322 — intervention group
Group type: EXPERIMENTAL
Intervention: NMAB-urea
Number of subjects: 0
Study 7629322 — intervention group
Group type: COMPARATOR
Intervention: Sodium hypochlorite
Number of subjects: 0
Study 7629322 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 7629322 — intervention group
Group type: COMPARATOR
Intervention: Urea
Number of subjects: 0
Study 7629322 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical caries removal solutions
Number of subjects: 0
Study 2242508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2242508 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexedrine (5 mg)
Number of subjects: 12
Study 2242508 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 12
Study 327758 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate treatment
Number of subjects: 16
Study 30670263 — intervention group
Group type: EXPERIMENTAL
Intervention: SWs causing mild pain (SW‐DP)
Number of subjects: 63
Study 30670263 — intervention group
Group type: EXPERIMENTAL
Intervention: SWs generating moderate pain (SW‐MP)
Number of subjects: 63
Study 30670263 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test (CPT)
Number of subjects: 63
Study 28367667 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D vision and haptic feedback in virtual reality
Number of subjects: 20
Study 28367667 — intervention group
Group type: COMPARATOR
Intervention: Control group without 3D vision and haptic feedback
Number of subjects: 20
Study 27330026 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonial therapy
Number of subjects: 0
Study 27330026 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 24671501 — intervention group
Group type: EXPERIMENTAL
Intervention: Leining (10 mg/kg)
Number of subjects: 440
Study 24671501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 22203317 — intervention group
Group type: EXPERIMENTAL
Intervention: RX-10100 5 mg twice daily
Number of subjects: 77
Study 22203317 — intervention group
Group type: EXPERIMENTAL
Intervention: RX-10100 10 mg twice daily
Number of subjects: 77
Study 22203317 — intervention group
Group type: EXPERIMENTAL
Intervention: RX-10100 15 mg twice daily
Number of subjects: 77
Study 22203317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 22203317 — intervention group
Group type: EXPERIMENTAL
Intervention: RX-10100 5 mg twice daily (severe depression subgroup)
Number of subjects: 77
Study 22203317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (severe depression subgroup)
Number of subjects: 77
Study 22203317 — intervention group
Group type: EXPERIMENTAL
Intervention: RX-10100 5 mg twice daily (responders)
Number of subjects: 77
Study 20101512 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg atropine
Number of subjects: 70
Study 20101512 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline
Number of subjects: 70
Study 18022750 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 18022750 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanol
Number of subjects: 0
Study 18022750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0
Study 18022750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone
Number of subjects: 0
Study 18022750 — intervention group
Group type: EXPERIMENTAL
Intervention: Eta‐butanol
Number of subjects: 0
Study 18022750 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMA
Number of subjects: 0
Study 18022750 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond NT (adhesive resin) after 24h water storage
Number of subjects: 0
Study 18022750 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond NT (adhesive resin) after dry storage
Number of subjects: 0
Study 15895228 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Number of subjects: 24
Study 11872328 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14
Study 11872328 — intervention group
Group type: COMPARATOR
Intervention: Control amino-acid drink
Number of subjects: 14
Study 10421219 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP step II diet at isoweight energy
Number of subjects: 20
Study 10421219 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP hypocaloric diet (15% less than isoweight)
Number of subjects: 20
Study 10421219 — intervention group
Group type: COMPARATOR
Intervention: High-fat, high-saturated-fat diet (baseline)
Number of subjects: 20
Study 7593098 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression
Number of subjects: 33
Study 7593098 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 33
Study 1345041 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliomolar
Number of subjects: 142
Study 1345041 — intervention group
Group type: EXPERIMENTAL
Intervention: J&J Experimental (Adaptic II)
Number of subjects: 142
Study 1345041 — intervention group
Group type: EXPERIMENTAL
Intervention: P-30
Number of subjects: 142
Study 1345041 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon
Number of subjects: 142
Study 6559719 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2-Gel without prior treatment with Betamimetica (n = 6)
Number of subjects: 30
Study 6559719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (5 mb) administered 30 minutes prior to PGE2-Gel (n = 6)
Number of subjects: 30
Study 6559719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine (10 mg) administered 30 minutes prior to PGE2-Gel (n = 6)
Number of subjects: 30
Study 6559719 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (20 micrograms) administered 30 minutes prior to PGE2-Gel (n = 6)
Number of subjects: 30
Study 6559719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Gel without PGE2) (n = 6)
Number of subjects: 30
Study 6559719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (5 mb)
Number of subjects: 30
Study 31597934 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 134
Study 31597934 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 134
Study 28985294 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial outreach to 114 practices, 52 (45%) practices responded with interest.
Number of subjects: 25
Study 28985294 — intervention group
Group type: EXPERIMENTAL
Intervention: Average time to enroll practices was 71 calendar days (range 11‐107).
Number of subjects: 25
Study 28985294 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment duration based on organization size (large vs small).
Number of subjects: 25
Study 28985294 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment barriers identified.
Number of subjects: 25
Study 26574566 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Monitoring Blood Pressure (SMBP)
Number of subjects: 224